A Phase 1 trial: MEU Phase 1 Clinic: SUDO-286-102
This is an early-stage medical study, often called a Phase 1 trial. The organisation that oversees health research, the Health Research Authority (HRA), has approved that the full details of this particular study will not be made public immediately. Instead, all the information will be officially released and added to public records within 30 months (about two and a half years) after the study has come to an end. This means that at the moment, many of the specifics about what the study is testing, why it's being done, and who can take part are not available for public review. It's a common practice for early research to keep some details private initially, especially when developing new treatments.
At a glance
What is this study about?
This study is a Phase 1 trial, which is one of the very first steps when exploring new medical treatments or approaches. Think of it like a brand new recipe being tested in a small kitchen before it goes into a big restaurant. Because it's so early, the organisation that checks health studies in the UK, called the Health Research Authority (HRA), has given permission for the full details of this trial to be kept private for now.
This is quite common in early research. It allows the researchers to gather initial information without revealing everything right away, especially if they are working on something very innovative. The HRA ensures that even with deferred publication, the study is still ethical and safe for participants.
Rest assured, all the information about what this study was about will eventually be made public. This will happen within 30 months (which is two and a half years) after the entire study has finished. So, while we don't have the specifics now, they will be shared transparently in due course for everyone to see and understand.
Key takeaways
- This is an early-stage medical study (Phase 1).
- Full details about the study are not yet publicly available.
- The Health Research Authority (HRA) has approved this deferral.
- All study information will be released within 30 months after the trial ends.
- The study primarily focuses on checking safety and dosage.
Who may be eligible?
At this time, the specific rules about who can and can't join this study are not publicly available. This information is usually very detailed, explaining things like age, other health conditions, and any medicines a person might be taking.
Normally, in any medical study, there are clear guidelines called 'inclusion' and 'exclusion' criteria. 'Inclusion' criteria are the things that mean you might be able to take part, like being within a certain age range or having a particular health condition. 'Exclusion' criteria are reasons why you would not be able to join, such as having another serious illness or taking certain medications.
For this particular study, these important details will be shared publicly within 30 months after the study has concluded. If you are interested in future studies of a similar nature, always discuss your health with your doctor or the research team to see if you might be a good fit.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I understand that eligibility details are not currently public.
- I know that who can join will be kept private for a while.
- I understand that this is an early-stage trial.
- I know that all sexes are generally considered for this type of study.
- I understand that specific age limits are not public at this time.
What does participation involve?
As the full details of this study are currently confidential, we don't have specific information about what taking part would involve. Usually, in early-stage (Phase 1) studies, participants might need to visit the study clinic regularly for check-ups, blood tests, or other assessments. They might also receive the new treatment or medication being tested.
The number of visits, the types of tests, and how long the study lasts can vary a lot depending on what's being researched. Often, participants in Phase 1 trials are closely monitored for a period to make sure the new treatment is safe. After a treatment period, there's usually a follow-up phase to see how people are doing. All these details would be clearly explained to potential participants if they were considering joining.
Potential risks and benefits
Locations (1)
- Medicines Evaluation Unit LimitedCity onlyManchester, England
Common questions
What is a Phase 1 trial?
A Phase 1 trial is one of the very first studies of a new treatment or medicine in people. It mainly aims to check if it's safe and to find the right dose, usually involving a small number of participants.
Why aren't the study details available now?
The Health Research Authority (HRA) has allowed the researchers to keep the full details private for a while. This is sometimes done in early research, especially when developing innovative treatments.
When will the full study details be shared?
All the details will be made public and added to the study records within 30 months (about two and a half years) after the trial has completely finished.
Can I still find out more or take part?
Because the details are deferred, we don't have information on how to participate or specific contact details. If you're interested in clinical trials, speak to your doctor.
What is the Health Research Authority (HRA)?
The HRA is an organisation in the UK that protects the rights, safety, and wellbeing of people taking part in health research. They approve and oversee studies.
How to find out more
Ian Mills
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.